Lipocine Historical Balance Sheet

LPCN Stock

USD 3.54 0.04 1.14%

Trend analysis of Lipocine balance sheet accounts such as Total Stockholder Equity of 24.5 M provides information on Lipocine's total assets, liabilities, and equity, which is the actual value of Lipocine to its prevalent stockholders. By breaking down trends over time using Lipocine balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Lipocine latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lipocine is a good buy for the upcoming year.

Lipocine Inventory

0.95

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

About Lipocine Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Lipocine at a specified time, usually calculated after every quarter, six months, or one year. Lipocine Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lipocine and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lipocine currently owns. An asset can also be divided into two categories, current and non-current.

Lipocine Balance Sheet Chart

At this time, Lipocine's Common Stock Total Equity is very stable compared to the past year. As of the 22nd of March 2025, Common Stock Shares Outstanding is likely to grow to about 5.7 M, while Total Current Liabilities is likely to drop about 1.4 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Lipocine assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lipocine books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Lipocine balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lipocine are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Lipocine's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lipocine current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.At this time, Lipocine's Common Stock Total Equity is very stable compared to the past year. As of the 22nd of March 2025, Common Stock Shares Outstanding is likely to grow to about 5.7 M, while Total Current Liabilities is likely to drop about 1.4 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	1.1M	1.2M	921.2K	1.5M
Total Assets	37.5M	23.0M	22.5M	29.4M

Other Current Liab Total Assets

Lipocine balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Debt	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Retained Earnings Total Equity	Short Term Investments	Capital Surpluse	Treasury Stock	Property Plant And Equipment Net	Non Current Assets Total
Total Assets		0.4	0.43	0.96	-0.25	-0.5	-0.49	0.51	0.51	0.36	0.99	0.39	0.46	0.11	0.65	0.19	1.0	0.43	-0.09	0.88	-0.54	0.65	0.62	-0.52	0.16	0.55
Other Current Liab	0.4		0.62	0.35	-0.04	-0.01	-0.32	0.18	-0.03	0.04	0.38	0.12	0.17	-0.02	0.36	0.21	0.41	0.12	0.08	0.3	-0.36	0.46	0.34	-0.52	0.18	0.13
Total Current Liabilities	0.43	0.62		0.2	-0.1	0.08	-0.54	0.73	0.06	-0.02	0.31	0.24	0.23	0.58	0.58	0.85	0.42	0.36	-0.53	0.14	-0.65	0.31	0.56	-0.64	-0.33	0.25
Total Stockholder Equity	0.96	0.35	0.2		-0.24	-0.56	-0.37	0.35	0.51	0.39	0.99	0.35	0.43	-0.06	0.53	-0.08	0.96	0.37	0.08	0.93	-0.39	0.65	0.51	-0.38	0.27	0.54
Other Liab	-0.25	-0.04	-0.1	-0.24		-0.14	0.64	-0.29	0.15	-0.72	-0.22	-0.79	-0.78	-0.16	-0.59	0.03	-0.22	-0.74	-0.26	-0.4	0.59	-0.38	-0.59	0.35	-0.46	-0.32
Net Debt	-0.5	-0.01	0.08	-0.56	-0.14		-0.18	-0.19	-0.97	0.24	-0.58	0.19	0.18	0.07	0.04	0.19	-0.55	0.19	0.13	-0.49	-0.17	0.25	0.05	-0.13	0.03	0.19
Retained Earnings	-0.49	-0.32	-0.54	-0.37	0.64	-0.18		-0.57	0.1	-0.69	-0.42	-0.88	-0.88	-0.36	-0.96	-0.44	-0.48	-0.86	-0.19	-0.51	0.99	-0.57	-0.95	0.82	-0.46	-0.32
Accounts Payable	0.51	0.18	0.73	0.35	-0.29	-0.19	-0.57		0.31	0.17	0.43	0.41	0.39	0.52	0.64	0.65	0.51	0.57	-0.45	0.35	-0.64	0.21	0.61	-0.43	-0.32	0.29
Cash	0.51	-0.03	0.06	0.51	0.15	-0.97	0.1	0.31		-0.29	0.57	-0.18	-0.19	0.13	0.02	0.03	0.57	-0.18	-0.3	0.42	0.07	-0.3	0.01	0.04	-0.14	-0.21
Other Assets	0.36	0.04	-0.02	0.39	-0.72	0.24	-0.69	0.17	-0.29		0.33	0.91	0.92	-0.09	0.65	-0.16	0.31	0.81	0.46	0.57	-0.61	0.64	0.65	-0.35	0.61	0.57
Cash And Short Term Investments	0.99	0.38	0.31	0.99	-0.22	-0.58	-0.42	0.43	0.57	0.33		0.34	0.42	0.02	0.58	0.06	0.99	0.36	-0.01	0.91	-0.45	0.62	0.56	-0.46	0.22	0.48
Common Stock Total Equity	0.39	0.12	0.24	0.35	-0.79	0.19	-0.88	0.41	-0.18	0.91	0.34		0.99	0.18	0.82	0.11	0.36	0.92	0.33	0.53	-0.82	0.54	0.81	-0.55	0.56	0.43
Common Stock Shares Outstanding	0.46	0.17	0.23	0.43	-0.78	0.18	-0.88	0.39	-0.19	0.92	0.42	0.99		0.14	0.84	0.07	0.43	0.92	0.39	0.6	-0.82	0.64	0.83	-0.59	0.59	0.48
Other Current Assets	0.11	-0.02	0.58	-0.06	-0.16	0.07	-0.36	0.52	0.13	-0.09	0.02	0.18	0.14		0.35	0.66	0.12	0.25	-0.49	-0.1	-0.43	-0.1	0.33	-0.32	-0.35	0.01
Other Stockholder Equity	0.65	0.36	0.58	0.53	-0.59	0.04	-0.96	0.64	0.02	0.65	0.58	0.82	0.84	0.35		0.43	0.64	0.88	0.13	0.66	-0.96	0.65	0.99	-0.83	0.39	0.42
Total Liab	0.19	0.21	0.85	-0.08	0.03	0.19	-0.44	0.65	0.03	-0.16	0.06	0.11	0.07	0.66	0.43		0.19	0.21	-0.68	-0.15	-0.54	0.04	0.41	-0.52	-0.48	0.08
Total Current Assets	1.0	0.41	0.42	0.96	-0.22	-0.55	-0.48	0.51	0.57	0.31	0.99	0.36	0.43	0.12	0.64	0.19		0.39	-0.09	0.88	-0.53	0.6	0.61	-0.52	0.17	0.47
Common Stock	0.43	0.12	0.36	0.37	-0.74	0.19	-0.86	0.57	-0.18	0.81	0.36	0.92	0.92	0.25	0.88	0.21	0.39		0.21	0.55	-0.83	0.59	0.88	-0.56	0.37	0.54
Property Plant Equipment	-0.09	0.08	-0.53	0.08	-0.26	0.13	-0.19	-0.45	-0.3	0.46	-0.01	0.33	0.39	-0.49	0.13	-0.68	-0.09	0.21		0.25	-0.07	0.26	0.14	-0.11	0.9	-0.12
Net Tangible Assets	0.88	0.3	0.14	0.93	-0.4	-0.49	-0.51	0.35	0.42	0.57	0.91	0.53	0.6	-0.1	0.66	-0.15	0.88	0.55	0.25		-0.49	0.65	0.66	-0.42	0.46	0.45
Retained Earnings Total Equity	-0.54	-0.36	-0.65	-0.39	0.59	-0.17	0.99	-0.64	0.07	-0.61	-0.45	-0.82	-0.82	-0.43	-0.96	-0.54	-0.53	-0.83	-0.07	-0.49		-0.59	-0.95	0.86	-0.35	-0.37
Short Term Investments	0.65	0.46	0.31	0.65	-0.38	0.25	-0.57	0.21	-0.3	0.64	0.62	0.54	0.64	-0.1	0.65	0.04	0.6	0.59	0.26	0.65	-0.59		0.64	-0.57	0.37	0.76
Capital Surpluse	0.62	0.34	0.56	0.51	-0.59	0.05	-0.95	0.61	0.01	0.65	0.56	0.81	0.83	0.33	0.99	0.41	0.61	0.88	0.14	0.66	-0.95	0.64		-0.81	0.41	0.41
Treasury Stock	-0.52	-0.52	-0.64	-0.38	0.35	-0.13	0.82	-0.43	0.04	-0.35	-0.46	-0.55	-0.59	-0.32	-0.83	-0.52	-0.52	-0.56	-0.11	-0.42	0.86	-0.57	-0.81		-0.35	-0.24
Property Plant And Equipment Net	0.16	0.18	-0.33	0.27	-0.46	0.03	-0.46	-0.32	-0.14	0.61	0.22	0.56	0.59	-0.35	0.39	-0.48	0.17	0.37	0.9	0.46	-0.35	0.37	0.41	-0.35		-0.07
Non Current Assets Total	0.55	0.13	0.25	0.54	-0.32	0.19	-0.32	0.29	-0.21	0.57	0.48	0.43	0.48	0.01	0.42	0.08	0.47	0.54	-0.12	0.45	-0.37	0.76	0.41	-0.24	-0.07

Click cells to compare fundamentals

Lipocine Account Relationship Matchups

Lipocine balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	25.4M	52.5M	37.5M	23.0M	22.5M	29.4M
Other Current Liab	1.7M	2.0M	1.1M	1.2M	921.2K	1.5M
Total Current Liabilities	6.6M	5.6M	1.7M	2.6M	1.5M	1.4M
Total Stockholder Equity	15.3M	45.6M	35.6M	20.4M	21.0M	24.5M
Net Debt	(13.6M)	(639.7K)	(3.1M)	(4.8M)	(6.2M)	(6.5M)
Retained Earnings	(172.0M)	(172.7M)	(183.4M)	(199.8M)	(199.8M)	(189.8M)
Accounts Payable	1.6M	1.3M	600.4K	1.4M	271.7K	258.1K
Cash	19.2M	3.0M	3.1M	4.8M	6.2M	8.9M
Cash And Short Term Investments	19.7M	44.6M	32.5M	22.0M	21.6M	26.4M
Common Stock Total Equity	2.2K	3.8K	7.0K	8.8K	10.2K	10.7K
Common Stock Shares Outstanding	3.3M	5.2M	5.3M	5.3M	5.4M	5.7M
Liabilities And Stockholders Equity	25.4M	52.5M	37.5M	23.0M	22.5M	29.4M
Other Current Assets	5.7M	1.5M	945.3K	773.4K	688.4K	653.9K
Other Stockholder Equity	187.4M	218.2M	219.1M	220.1M	220.8M	154.4M
Total Liab	10.0M	6.9M	1.9M	2.6M	1.5M	1.4M
Total Current Assets	25.3M	46.4M	34.1M	22.9M	22.3M	28.5M
Common Stock	7.0K	8.8K	8.9K	8.9K	8.9K	4.5K
Property Plant Equipment	19.0K	3.6K	7.2K	131.6K	118.4K	124.4K
Net Tangible Assets	6.3M	15.3M	45.6M	35.6M	41.0M	27.0M
Retained Earnings Total Equity	(138.1M)	(151.1M)	(172.0M)	(172.7M)	(155.4M)	(163.2M)
Short Term Investments	450.0K	41.7M	29.4M	17.3M	15.4M	15.2M
Capital Surpluse	147.5M	157.4M	187.4M	218.3M	251.0M	143.4M
Property Plant And Equipment Net	0.0	7.2K	131.6K	116.1K	165.1K	173.3K
Non Current Assets Total	23.8K	6.1M	3.4M	139.8K	188.8K	179.4K
Property Plant And Equipment Gross	1.1M	1.2M	1.3M	1.3M	1.4M	1.5M
Net Receivables	391.0	247.3K	659.9K	52.3K	47.0K	44.7K
Net Invested Capital	20.9M	47.9M	35.6M	20.4M	21.0M	27.2M
Net Working Capital	18.7M	40.8M	32.5M	20.2M	20.8M	25.1M
Short Long Term Debt Total	7.1M	5.6M	2.3M	17.2K	15.4K	14.7K
Capital Stock	7.0K	8.8K	8.9K	8.9K	8.9K	7.6K

When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:

How To Invest In Lipocine

Details

Is Lipocine Stock a good investment?

Details

What is Lipocine's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Revenue Per Share

2.097

Quarterly Revenue Growth

15.15

Return On Assets

(0.03)

Return On Equity

0.0004

The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lipocine Historical Balance Sheet

Lipocine Inventory

0.95

About Lipocine Balance Sheet Analysis

Lipocine Balance Sheet Chart

Total Assets

Total Current Liabilities

Lipocine balance sheet Correlations

Lipocine Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lipocine balance sheet Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Retained Earnings Total Equity	+ 0.99	Retained Earnings
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock Shares Outstanding	+ 0.99	Common Stock Total Equity

Cash	- 0.97	Net Debt
Retained Earnings Total Equity	- 0.96	Other Stockholder Equity
Other Stockholder Equity	- 0.96	Retained Earnings
Capital Surpluse	- 0.95	Retained Earnings Total Equity
Capital Surpluse	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.88	Retained Earnings